Metrion Biosciences Expands Operations

Expansion of its CRO and collaborative drug discovery business has led Metrion Biosciences to relocate to larger laboratories at Granta Park, Cambridge from its former premises at the Babraham Research Campus. The company has also appointed Dr Andrew Southan as Head of Commercial Operations and three additional senior scientists.

The Company has grown rapidly since its formation in 2015 and has seen increased demand from major pharmaceutical and bioscience companies for its cardiotoxicity and neurological safety assays and ion channel drug discovery research expertise.

Dr Southan joins from Charles River Laboratories where he was Director of Ion Channel Biology. He has over 25 years’ experience within the life science industry, including 14 years managing services in the CRO sector at CeNeS Pharmaceuticals, BioFocus and Charles River.

He also brings significant experience of securing and managing discovery research across a wide range of therapeutically relevant target classes. Dr Marc Rogers, Chief Scientific Officer, Metrion Biosciences, said: “Since becoming an independent CRO in 2015 Metrion has grown rapidly. We are delighted to welcome Andrew as Head of Commercial Operations as we move into larger and better equipped laboratories. His excellent project management skills, business development credentials and scientific expertise are ideally suited for the new role and we look forward to working with him on our team.”

Dr Andrew Southan commented: “The Metrion Biosciences team’s ion channel expertise, quality of work, dedication to customers and highly competitive pricing structure offers a great opportunity to build for success and I look forward to contributing to the Company’s further development.”